Belgian Week of Gastroenterology

XXIst EDITION

ANTWERP, February 12-14, 2009

http://www.belgianweek.be
WELCOME ADDRESS

Dear Colleagues,

The Belgian Week of Gastroenterology 2009 is now launched!

We would like to invite you at our 21st Belgian Week of Gastroenterology taking place from February 12 till February 14, 2009 in the beautiful city of Antwerp.

Last year it was a big success and as we do not have many choices in Belgium for good locations for such a congress (599 participants in 2008), we preferred to come back in 2009 to the Hilton Hotel.

We hope it will be a remarkable congress:

- We had 106 submitted abstracts to the Joint meeting
- All research groups and scientific societies organized up-to-date programmes with a total of 234 communications and 22 invited guests.
- On the Saturday, the Six Societies Symposium is organised by the Belgian Society of Gastrointestinal Endoscopy with as title: “Premalignant lesions in the liver, pancreas and gastrointestinal tract.”

Please mark this symposium in your agenda!

The Brohée Price is awarded every 2 years and will be given this year to Wim Laleman. He will present his work on Saturday afternoon.

Of course I would like to stimulate you to come to our Gala Dinner with Party on Friday, February 13 in the fantastic Marble Hall of the Zoo with reception in the Winter Garden.

I would suggest that everybody takes the opportunity to invite his/her partner to come to Antwerp to celebrate Valentine Day, in this nice city with lot of facilities and nice shops.

A partner program will be provided in due time.

Antwerp is THE shopping city of Belgium with a magnificent architecture, fashionable shop fronts, beer-washed pubs, dazzling monuments, jazzed-up clubs, inspired artworks and restaurant tables piled with plates of superb Belgian and multicultural food.
We take the opportunity to thank all presenters, authors, organizers, and moderators for their active participation to bring our Joint Meeting and Belgian Week to its highest value.

The success of our Belgian Week is also related to our partnership with the Biomedical Industry, which has supported our previous meetings by specific sponsorships, educational grants and invitations of Belgian participants. We are therefore pleased to thank all our partners for their continuing support and especially our premium partners Abbott, AstraZeneca, Gilead, Nycomed, Schering-Plough, and our major partners Bayer and Roche.

We sincerely hope that you will enjoy your stay in Antwerp and that you will join us for our Friday night party at the Marble Hall of the Zoo.

Isabelle Colle
Scientific Coordinator

NB.


All abstracts of lectures will be published in Acta Gastroenterologica Belgica. Acta Gastroenterologica is accessible on internet:
www.acta-gastroenterologica.be

P. Deprez, Editor in chief
P. Michielsen, Deputy Editor
# INDEX

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SATELLITE SYMPOSIA</td>
<td>7</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>8</td>
</tr>
<tr>
<td>STEERING COMMITTEE</td>
<td>9</td>
</tr>
<tr>
<td>INVITED LECTURES</td>
<td>10</td>
</tr>
<tr>
<td><strong>THURSDAY FEBRUARY 12</strong></td>
<td></td>
</tr>
<tr>
<td>BASL</td>
<td>12</td>
</tr>
<tr>
<td>OG – FWO</td>
<td>14</td>
</tr>
<tr>
<td>BELGIAN PANCREATIC CLUB</td>
<td>19</td>
</tr>
<tr>
<td>IBD RESEARCH GROUP</td>
<td>20</td>
</tr>
<tr>
<td>BHPSG GROUP</td>
<td>21</td>
</tr>
<tr>
<td>BELGIAN CAPSULE GROUP</td>
<td>23</td>
</tr>
<tr>
<td>JOINT MEETING : Session A</td>
<td>24</td>
</tr>
<tr>
<td>JOINT MEETING : Session B</td>
<td>25</td>
</tr>
<tr>
<td><strong>PROGRAM OVERVIEW</strong></td>
<td>26</td>
</tr>
<tr>
<td><strong>FRIDAY FEBRUARY 13</strong></td>
<td></td>
</tr>
<tr>
<td>JOINT MEETING : Plenary Session C</td>
<td>28</td>
</tr>
<tr>
<td>JOINT MEETING : Plenary Session D</td>
<td>29</td>
</tr>
<tr>
<td>JOINT MEETING : Plenary Session E</td>
<td>30</td>
</tr>
<tr>
<td>JOINT MEETING : Plenary Session F</td>
<td>31</td>
</tr>
<tr>
<td>PATHOLOGY, RADIOLOGY and BGDO</td>
<td>32</td>
</tr>
<tr>
<td>PATHOLOGY, RADIOLOGY (afternoon session)</td>
<td>34</td>
</tr>
<tr>
<td>BGDO (afternoon session)</td>
<td>36</td>
</tr>
<tr>
<td>BeSPGHAN</td>
<td>38</td>
</tr>
<tr>
<td>NUTRITION GROUP</td>
<td>39</td>
</tr>
</tbody>
</table>
POSTER SESSIONS:

- BASL 40
- BeSPGHAN 43
- JOINT MEETING 44

SATURDAY FEBRUARY 14:

6 SOCIETIES SYMPOSIUM:

- « 2009 : Premalignant lesions in the liver, pancreas and gastrointestinal tract » 46
- BWG 2009 Awards 46
- BROHÉE PRIZE Award & Lecture 47

ACCESS TO THE CONGRESS VENUE 48

FRIDAY NIGHT PARTY 50

BWG 2009 PARTNERS 51
Insufficient renal or hepatic function:
- Hepatic or biliary insufficiency: Augmentation of liver enzymes. – Rare
- Nier- or urinary tract diseases: Hematuria, renal insufficiency, bladder- and urethra symptoms. – Rare
- Proteinsuria, renal pain.

Indication of emergency:
- In case of emergency, inject 160 mg intravenously over 15 to 20 minutes. If this is not possible, inject 160 mg via subcutaneous injection at the same time as an intravenous injection. If this is not possible, inject 160 mg subcutaneously 30 minutes after the intravenous injection. If this is not possible, inject 160 mg subcutaneously within 24 hours. If 40 mg daily subcutaneous treatment is continued, the recommended dose is 40 mg every second week. If it is necessary to obtain a faster response to the treatment, the schedule 160 mg at week 0, 160 mg at week 2, may be used, knowing that the risk of side effects is higher during the induction. After the induction treatment, the recommended dose is 40 mg every second week. Should the response not improve within these time limits, Humira therapy should be carefully re-evaluated in a patient who has not responded in these timeframes.

Immune system disorders:
- Occasionally: Infections of the skin and subcutaneous tissue, in the respiratory tract, haematological, cardiovascular.
- Rare: Infections of the digestive system, in the urinary tract.

Hematological disorders:
- Insufficient red blood cell production, anaemia, infections of the blood.

Special senses:
- Occasionally: Vertigo, headache, neurological sensations (including paresthesia) – Rare: Syncope, migraine, tremor, sleep disorders. - Zelden: Multiple sclerosis, facial paralysis.

Infections and infestations:
- Common: colds, influenza, bronchitis, sinusitis, pharyngitis, otitis media, ear infections, infections of the skin, in the eye, in the ear, infections of the urinary tract, infections of the gastrointestinal tract, infections of the respiratory tract, infections of the genitourinary tract, infections of the central nervous system, infections of the peripheral nervous system.

Maternal and foetal disorders:
- Occasionally: Endometriosis, in the frequency of menstruation and uterine bleeding disorders in women. – Rare: Insufficient menstrual blood loss in women. The function of the female reproductive system is maintained in the treatment with Humira, in the absence of pregnancy. When used, Humira can be continued until the end of pregnancy without concern for the health of the foetus. In case of emergency, inject 160 mg intravenously over 15 to 20 minutes. If this is not possible, inject 160 mg via subcutaneous injection at the same time as an intravenous injection. If this is not possible, inject 160 mg subcutaneously 30 minutes after the intravenous injection. If this is not possible, inject 160 mg subcutaneously within 24 hours. If 40 mg daily subcutaneous treatment is continued, the recommended dose is 40 mg every second week. If it is necessary to obtain a faster response to the treatment, the schedule 160 mg at week 0, 160 mg at week 2, may be used, knowing that the risk of side effects is higher during the induction. After the induction treatment, the recommended dose is 40 mg every second week. Should the response not improve within these time limits, Humira therapy should be carefully re-evaluated in a patient who has not responded in these timeframes.

Central nervous system disorders:
- Occasionally: Dizziness, in the frequency of headaches, neurological sensations (including paresthesia) – Rare: Syncope, migraine, tremor, sleep disorders. - Zelden: Multiple sclerosis, facial paralysis.

Genitourinary disorders:
- Occasionally: Infections of the genitourinary tract, in the frequency of menstruation and uterine bleeding disorders in women. – Rare: Insufficient menstrual blood loss in women. When used, Humira can be continued until the end of pregnancy without concern for the health of the foetus. In case of emergency, inject 160 mg intravenously over 15 to 20 minutes. If this is not possible, inject 160 mg via subcutaneous injection at the same time as an intravenous injection. If this is not possible, inject 160 mg subcutaneously 30 minutes after the intravenous injection. If this is not possible, inject 160 mg subcutaneously within 24 hours. If 40 mg daily subcutaneous treatment is continued, the recommended dose is 40 mg every second week. If it is necessary to obtain a faster response to the treatment, the schedule 160 mg at week 0, 160 mg at week 2, may be used, knowing that the risk of side effects is higher during the induction. After the induction treatment, the recommended dose is 40 mg every second week. Should the response not improve within these time limits, Humira therapy should be carefully re-evaluated in a patient who has not responded in these timeframes.

Pregnancy:
- Occasionally: Endometriosis, in the frequency of menstruation and uterine bleeding disorders in women. – Rare: Insufficient menstrual blood loss in women. The function of the female reproductive system is maintained in the treatment with Humira, in the absence of pregnancy. When used, Humira can be continued until the end of pregnancy without concern for the health of the foetus. In case of emergency, inject 160 mg intravenously over 15 to 20 minutes. If this is not possible, inject 160 mg via subcutaneous injection at the same time as an intravenous injection. If this is not possible, inject 160 mg subcutaneously 30 minutes after the intravenous injection. If this is not possible, inject 160 mg subcutaneously within 24 hours. If 40 mg daily subcutaneous treatment is continued, the recommended dose is 40 mg every second week. If it is necessary to obtain a faster response to the treatment, the schedule 160 mg at week 0, 160 mg at week 2, may be used, knowing that the risk of side effects is higher during the induction. After the induction treatment, the recommended dose is 40 mg every second week. Should the response not improve within these time limits, Humira therapy should be carefully re-evaluated in a patient who has not responded in these timeframes.

In case of emergency, inject 160 mg intravenously over 15 to 20 minutes. If this is not possible, inject 160 mg via subcutaneous injection at the same time as an intravenous injection. If this is not possible, inject 160 mg subcutaneously 30 minutes after the intravenous injection. If this is not possible, inject 160 mg subcutaneously within 24 hours. If 40 mg daily subcutaneous treatment is continued, the recommended dose is 40 mg every second week. If it is necessary to obtain a faster response to the treatment, the schedule 160 mg at week 0, 160 mg at week 2, may be used, knowing that the risk of side effects is higher during the induction. After the induction treatment, the recommended dose is 40 mg every second week. Should the response not improve within these time limits, Humira therapy should be carefully re-evaluated in a patient who has not responded in these timeframes.
ROOM LIJN

13h15-14h00  BAYER
Sorafenib: Clinical practice in advanced HCC.
Speaker: C. Verslype / UZ Leuven
Moderator: I. Colle / UZ Gent

ROOM LIJN

17h30-18h15  SCHERING PLOUGH
Landmark data in IBD patients.
Speakers: S. Ghosh / Calgary, Canada
G. D’Haens / Bonheiden
P. Rutgeerts / KULeuven
Moderator: E. Louis / ULg

ROOM LIJN

18h15-19h00  MERCK
Erbitux: from third to first line treatment in mCRC.
Speakers: E. Van Cutsem / KULeuven
M. Peeters / UZ Gent
J.F. Gigot / UCL Saint-Luc
Moderator: J.L. Van Laethem / ULB Erasme

ROOM TEUN / LIJN

13h15-14h00  DANONE
Probiotics and Irritable Bowel Syndrome.
Speaker: P. Whorwell / Manchester, U.K.
Moderators: J. Tack / KULeuven
H. Piessevaux / UCL Saint-Luc

ROOM TEUN / LIJN

17h30-18h15  NYCOMED
Acid related disorders.
Speakers: R. Bergman / Amsterdam, the Netherlands
J. Tack / KULeuven
J. Sung / Hong Kong, China
Moderators: R. Bisschops / KULeuven
P. Deprez / UCL Saint-Luc

ROOM TEUN / LIJN

18h15-19h00  GILEAD
Tenofovir for HBV: 96 weeks data from two pivotal phase III clinical trials.
GENERAL INFORMATION

ACCREDITATION
Certificates for accreditation will be provided at the end of each 1/2 day session (3CP units) to the registered delegates who have attended the respective sessions. (Type-Rubriek 3, CP18, organizer 2730, Belgian Week of Gastroenterology)

LANGUAGE
Dutch, French and English. English (British spelling) for abstracts, slides and announcements.

ABSTRACTS
Authors were invited to send abstracts through the congress website until November 30th and to choose either the «Joint Meeting» (Clinical and Basic Research with clinical impact) or the appropriate Research Groups. 106 abstracts were submitted to the Joint meeting and in total we received 234 abstracts, research groups included! The Joint Meeting oral presentations were selected by the Joint Meeting Selection Committee and will be presented on Thursday afternoon and on Friday. The Research Groups oral presentations were selected by the Selection Committee of each group.

For the Joint Meeting, the abstracts were scored ANONYMOUSLY from 0 to 10, on the basis of originality and scientific value by each of the members of the Selection Committee. It gathers experts in the different fields of Gastroenterology. The abstracts were then separated into several categories, the highest scores being presented during the Plenary Session on Friday morning, in increasing order of scores.

Prizes will be awarded on Saturday morning for the two best oral presentations at the Joint Meeting in Basic Research and Clinical Research. This year the BGDO will also present an award for the best communication in Oncology. The best IBD abstract will be awarded by both IBD patient associations. On Thursday noon, 2 BASL prizes will be awarded at the end of the morning session for the best basic & clinical oral presentation in hepatology.

VENUE
Hilton Antwerp Hotel – Groenplaats – 2000 Antwerp
Tel: +32 3 204 12 12 / Fax: +32 3 204 86 88.
The Conference Centre has separate elevators to access from the lobby of the Hotel. The 3rd floor is the main floor of the congress where you will find: the Registration, some Conference Rooms and the Exhibition room.

PARKING
Here are the closest parkings to the Hilton Antwerp:
- Groenplaats Parking: The Hilton Antwerp has reserved 200 places for our congress. Price per day: 13,5 €
- Meir Parking: Price per day: 13,5 €
- Brabo Parking: Price per day: 15 €
- Lombardia Parking: Thursday & Friday the price per day: 13,5 € Saturday the price per day: 15 €

EVENT COORDINATOR
Anne-France De Meyer – 102, av. J&P Carsoel – 1180 Brussels
Tel: +32 2 375 36 26 / Fax: +32 2 375 47 84 / E-mail: anne.france.de.meyer@skynet.be

HOTEL ROOMS AT THE HILTON
Please contact Anne-France De Meyer.

<table>
<thead>
<tr>
<th>Type room</th>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hilton Guest</td>
<td>199 €</td>
<td>219 €</td>
</tr>
<tr>
<td>Deluxe</td>
<td>249 €</td>
<td>259 €</td>
</tr>
<tr>
<td>Executive</td>
<td>279 €</td>
<td>289 €</td>
</tr>
</tbody>
</table>

ANTWERP TOURISM OFFICE
Tourism Antwerp – Grote Markt, 13 – 2000 Antwerp
Tel: +32 3 232 01 03 / E-mail: visit@antwerpen.be
STEERING COMMITTEE

Scientific Coordinator of the Joint Meeting

Isabelle COLLE

Six Societies

G. D’HAENS, G. VAN ASSCHE
(VVGE, Vlaamse Vereniging voor Gastro-Enterologie)

E. LOUIS, R. HUSTINX
(SRBBGE, Société Royale Belge de Gastro-Enterologie)

D. URBAIN, P. VAN DER SPEK
(BSGIE, Belgian Society of Gastrointestinal Endoscopy)

C. BERTRAND, T. GYS
(RBSS, Royal Belgian Society of Surgery)

B. OP DE BEECK, E. DANSE
(SRBR-KBVR, Royal Belgian Society of Radiology, Digestive Radiology and Abdominal Imaging)

J. DELWAIDE, I. COLLE
(BASL, Belgian Association for the Study of the Liver)

Scientific Secretaries of the Six Societies Symposium

Daniel URBAIN
Peter VANDERSPEK

Research Groups

I. DEPOORTERE, R. LEFEBVRE
(OG-FWO, Gastro-intestinal regulatory mechanisms)

J-L. VAN LAETHEM, M. POLUS
(BGDO, Belgian Group of Digestive Oncology)

K. GEBES, A. JOURET-MOURIN
(Gastro-Intestinal Pathology Club)

M. SCAILLON, B. HAUSER
(Be SPGHAN, Belgian Society for Paediatric Gastroenterology, Hepatology and Nutrition)

A. VAN GOSSUM
(SBNC, Société Belge de Nutrition Clinique)

D. YSEBAERT
(VVKVM, Vlaamse Vereniging voor Klinische Voeding en Metabolism)

E. LOUIS, S. VERMEIRE
(Belgian IBD Research Group)

M. DELHAYE
(BPC, Belgian Pancreatic Club)

V. GILLARD
(BGDE, Belgian Group of Digestive Endosonography)

V. LAMY, F. MANA
(BHPSG, Belgian Helicobacter Pylori Study Group)

D. URBAIN
(BVG, Belgian Videocapsule Group)

P. MICHIelsen, H. VAN VLIERBERGHE
(BLIC, Belgian Liver Intestine Committee)
INVITED LECTURES

BASL:

Rejection and immune tolerance.
A. Billiau / KU Leuven
12/02 - 12h15 – Room Lijn.

Belgian Pancreatic Club:

The dendritic therapy with its potential applications in pancreatic cancer.
S. Van Gool / KU Leuven
12/02 – 9h00 – Room Tiffany

New advances in genetics and pancreatic diseases.
C. Cano / Marseille, France
12/02 – 11h30 – Room Tiffany.

BGDO:

New functional imaging tools for tumor response evaluation.
D.M. Koh / Royal Marsden Hospital, U.K.
13/02 – 11h40 – Room Sancy

T. Lerut / UZ Leuven
13/02 – 14h00 – Room Florentine

BHP SG:

H. pylori and obesity/bariatric surgery.
R. Ntounda / ULB Saint-Pierre, Brussels
12/02 – 14h00 – Room Tiffany.

Pathology of Helicobacter suis in rodent models.
B. Flahou / UGent
12/02 – 14h20 – Room Tiffany.

IBD Research Group:

New trends in epidemiology of paediatric IBD.
G. Veereman / Queen Paola Children’s Hospital, Antwerp
12/02 – 14h00 – Room Sancy

Role of regulatory T cells in IBD.
A. Izcue / Oxford, U.K.
12/02 – 14h50 – Room Sancy.

New ECCO consensus on extra-intestinal manifestations of Crohn’s disease.
M. De Vos / UZ Gent
12/02 – 15h40 – Room Sancy.

New therapeutic strategies in IBD: blocking the traffic to the gut.
S. Ghosh / London, UK and Calgary, Canada
12/02 – 16h40 – Room Sancy.

Joint Meeting / BASL:

Marc Hautekeete lecture:
Resistance to HBV-HCV antiviral treatment.
F. Zoulim / Lyon, France
12/02 – 15h00 – Room Lijn.
OG – FWO:

**Gastrointestinal anti-inflammatory effects of hydrogen sulphide and hydrogen sulphide releasing molecules**

J. Wallace / Calgary, Canada
12/02 – 10h30 - Room Teun.

**Intestinal factors involved in the metabolic effects of dietary fructans.**

N. Delzenne / UCL
12/02 – 14h00 – Room Teun.

**Pathology / Radiology:**

**Colorectal cancer, KiRAS and the pathologist.**

J. Van Krieken / Nijmegen, The Netherlands
13/02 – 10h30 – Room Sancy.

**How close can be the radiologist with the pathologist for the local staging of colo-rectal cancer?**

E. Danse / UCL
13/02 – 13h30 – Room Sancy

**Radiological-pathological correlations in the staging of chronic liver disease.**

J. Cobbold / London, U.K.
13/02 – 16h00 – Room Sancy

**Brohé Prize:**

**Role of vasoactive substances and cellular effectors in the pathophysiology of portal hypertension: a study on the cellular, organ, experimental animal and human level.**

W. Laleman / KULeuven
14/02 – 14h00 – Room Teun/lijn.

**6 Societies Symposium:**

**Colorectal cancer precursors and non polypoid neoplastic lesions.**

R. Lambert / Lyon, France
14/02 – 9h00 – Room Teun/Lijn

**Appropriateness of colonoscopy in Europe.**

J.P. Vader / Lausanne, Switzerland
14/02 – 10h30 – Room Teun/Lijn

**Premalignant lesions of the stomach.**

A. de Vries / Rotterdam, The Netherlands
14/02 – 11h30 – Room Teun/Lijn

**Familial adenomatous polyposis: phenotype and genotype.**

A. Munck / Paris, France
14/02 – 12h00 – Room Teun/Lijn

**New evolutions in liver adenoma.**

P. Bioulac-Sage / Bordeaux, France
14/02 – 14h20 – Room Teun/Lijn
MODERATORS: H. REYNAERT, J.P. MULKAY

8.30 A01 Advanced glycation end products induce production of reactive oxygen species via activation of NADPH oxidase in hepatic stellate cells.
E. Guimarães, C. Empsen, L. Van Grunsven, A. Geerts / VUB Brussels

8.42 A02 Hepatitis B-delta virus co-infection in Belgium: preliminary data of the BASL HDV registry.

8.54 A03 Vitamins C and E combination therapy significantly improves most of the biochemical and histological changes of liver damage in CCL4 induced cirrhosis in rats.

9.06 A04 Impact of pegylated bitherapy on morbidity and mortality in patients with chronic hepatitis C and normal transaminases.

9.18 A05 Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE induced murine model of chronic liver injury.
N. Van Hul, J. Abarca-Quinones, C. Sempoux, Y. Horsmans, I. Leclercq / UCL

9.30 A06 Chronic administration of valproic acid inhibits complete activation of hepatic stellate cells in vitro and in vivo.
I. Mannaerts, N. Nuytten, A. Geerts, L. Van Grunsven / VUB

9.42 A07 Proliferation of hepatic stellate cells in rats with acute hepatitis is dependent on vagal innervation via muscarinic acetylcholine receptor subtype 2.
I. Bockx, N. Sinelli, I. Vander Elst, T. Roskams, D. Cassiman / KULeuven Gasthuisberg

9.54 A08 Anti-viral therapy in haemodialyzed HCV patients : efficacy, tolerance and treatment strategy.

10.06 A09 Satavaptan, a V2-receptor antagonist and aquaretic drug, improves portal hypertension in non-ascitic thioacetamide-induced cirrhotic rats.
L. Van Landeghem, W. Laleman, I. Vander Elst, J. Van Pelt, D. Cassiman, F. Nevens / KULeuven Gasthuisberg
10.18 Presentation of 6 abstracts accepted as posters (A18-A23) by the Moderator: H. Reynaert

10.28 COFFEE BREAK

SESSION 2

MODERATORS:  J. DELWAIDE, F. SERMON

10.40 A10 Antiviral treatment improves survival of patients with cholestatic fibrosing hepatitis after liver transplantation for hepatitis C.


10.52 A11 Kupffer cell depletion improves hepatic insulin sensitivity.

N. Lanthier, M. Petit, H. Pélier, J. Abarca, V. Lebrun, O. Molendi, D. Campard,

Y. Horsmans, I. Leclercq / UCL

11.04 A12 The interleukin-17 pathway is involved in human alcoholic liver disease.

A. Lemmers (1), C. Moreno (1), T. Gustot (1), R. Maréchal (1), D. Degré (1),
P. Demetter (1), P. De Nadai (2), A. Geerts (3), E. Quertinmont (1), V. Vercuyssse (1),

11.16 A13 Keratin 19 expression in hepatocellular carcinoma (HCC) is correlated with postoperative tumour recurrence and metastasis markers.

B. Spee (1), A. Durnez (1), S. Vanderborght (1), O. Govaere (1), V. Desmet (1),

11.28 A14 Distinct roles of nonmuscle myosin II isoforms in the regulation of mouse hepatic stellate cell contraction and migration.

Z. Liu (1), H. Reynaert (1), E. Van Rossen (1), L.A. Van Grunsven (1), B. Schroyen (1),


C. Moreno (1), P. Langlet (2), A. Hittelet (1), S. Evrand (1), L. Lasser (2), I. Colle (3), A. Lemmers (1),

11.52 A16 The presence of an inflammatory gene expression pattern in peritumoral liver tissue protects against development of macrovascular invasion and is decreased after anti angiogenic treatment with sunitinib in cirrhotic rats.

H. Van Vlierberghe, I. Colle, M. Praet, L. Libbrecht / UZ Gent

12.04 Presentation of 6 abstracts accepted as posters (A24-A29) by the Moderator: J. Delwaide

12.12 2 BASL Awards for the best basic and clinical work presented.

12.15 A17 INVITED LECTURE: The BASL-BLIC Spring Meeting lecture:
«Rejection and immune tolerance»

A. Billiau / KU Leuven

12.45-14.00 LUNCH
CHAIRMEN: I. DEPOORTERE, E. VAN MARCK

9.00  B01  The characterization of neuronal conduction and the functional role of tachykinins in colonic peristaltic activity of mice.
__________  A. Deiteren, B. De Winter, P. Pelckmans, J. De Man / UA Antwerp

9.15  B02  Somatostatin controls mast cell-induced responses of murine spinal neurons.
__________  J. Van Op den Bosch, L. Van Nassauw, E. Van Marck, J.P. Timmermans / UA Antwerp

9.30  B03  Motility peculiarities of foetal oesophagus and intestine used for cervical oesophagus replacement.
__________  V. Coulic (1), P. Delrée (2), E. Dekoster (1) / [1] ULB Brugmann, [2] IRSPG Gosselies,

9.45  B04  Esophageal mucosal damage induced by weakly acidic solutions containing unconjugated bile acids, similar to reflux in GERD patients on PPI, can be prevented with anti-oxidants.

10.00-10.30  COFFEE BREAK

CHAIRMEN: R. LEFEVBRE, J. TACK

10.30  B05  INVITED LECTURE: “Gastrointestinal anti-inflammatory effects of hydrogen sulphide and hydrogen sulphide releasing molecules”.
__________  J.L. Wallace / University of Calgary, Canada

11.15  B06  Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces the development of postoperative ileus induced by surgical manipulation of murine colon.
__________  O. De Backer, E. Elinck, B. Blanckaert, R. Lefebvre / U Gent

11.30  B07  TNBS-induced colitis influences colonic T cell cytokine profiles and causes gastrointestinal motility disorders in mice.

11.45  B08  Enteric 5-HT1A-like receptor density in colic horses suffering from small intestinal strangulation is associated with duration and serotonin (5-HT) levels in plasma and peritoneal fluid.
C. Reenaers, C. Libioulle, J. Belaiche, P. Delvenne, M. Georges, E. Louis / CHU Liege

12.15 B10 The impact of infliximab therapy on colonic mucosal expression of barrier genes in patients with inflammatory bowel disease.

12.30-14.00 LUNCH

• CHAIRMEN: B. DE WINTER, J.M. VANDERWINDEN

14.00 B11 INVITED LECTURE: “Intestinal factors involved in the metabolic effects of dietary Fructans”.
N. Delzenne / UCL

14.45 B12 Role of taste receptors in the regulation of ghrelin secretion.
S. Janssen, B. De Smet, P.J. Verhulst, T. Peeters, J. Tack, I. Depoortere / KULeuven

15.00 B13 Intragastric pressure during the drinking test.
P. Janssen, R. Vos, J. Tack / KULeuven

15.15 B14 Rimonabant-induced early satiety is associated with decreased gastric compliance and inhibition of gastric accommodation.
K. Ameloot, R. Vos, E. Scarpellini, P. Vanden Berghe, I. Depoortere, J. Tack / KULeuven

15.30 B15 Role of upper gastrointestinal motility stimulation in the occurrence of hunger peaks.
E. Scarpellini, R. Vos, H. Nicolai, D. Ang, P. Vanden Berghe, I. Depoortere, J. Tack / KULeuven

15.45 B16 Return of hunger after a meal: relation to gastric emptying and gastrointestinal motor patterns.
H. Nicolai, E. Scarpellini, R. Vos, I. Depoortere, P. Vanden Berghe, J. Tack / KULeuven

16.00-16.30 COFFEE BREAK
The cold and menthol receptor TRPM8 is expressed in epithelial cells of the human and murine gastric antrum.

W. Boesmans, V. Van Den Abbeel, G. Owsianik, T. Voets, J. Tack, P. Vanden Berghe / KULeuven

Neurochemical identification of specific subpopulations of enteric neurons in the larval and adult zebrafish (Danio rerio) intestine.


Contribution of hyperglycemia, HO-1 expression and inflammation to loss of nNOS and c-KIT expression in the spontaneously diabetic BioBreeding-rat.

S. Kindt, W. Boesmans, T. Masaoka, P. Vanden Berghe, J. Tack / KULeuven

Immunolocalization of novel ICC and GIST markers in the mouse antrum.


IC cilia: immunofluorescence of (immotile) cilium in KIT-IR interstitial cells of Cajal.

S. Ralea, P. Hague, J.M. Vanderwinden / ULB

INVITED LECTURE: “The intrinsic occult reflex regulates enteric neural activity in the colon”.

T. Smith, University of Nevada School of Medicine, Reno, USA

End of the Program
Nexiam®
esomeprazole

AstraZeneca®
**Gélules**

**Harde capsules**

Glyceryltrinitraat
rectale zalf

Trinitrate de glycéryle
pommade rectale
MODERATORS: P. DEPREZ, W. VAN STEENBERGEN

9.00 T01 INVITED LECTURE: The dendritic therapy with its potential applications in pancreatic cancer.
S. Van Gool, KULeuven Gasthuisberg

9.30 T02 Similarities between total mesorectal excision for rectal cancer and total mesoduodenal excision during pancreaticoduodenectomy for adenocarcinoma of the pancreatic head: the need for effective locoregional lymphadenectomy.
F. Berrevoet, F. Goudsmedt, L. Libbrecht, X. Rogiers, R. Troisi, M. Peeters,
B. de Hemptinne / UZ Gent

09.45 T03 When IgG4 and CA19-9 yield conflicting results in a patient with pancreatic disease: lessons to be learned.
W. Van Steenbergen, F. Claus, R. Aerts, T. Roskams / KULeuven Gasthuisberg

10.00 T04 Vitamin D deficiency in patients with chronic pancreatitis: a case-control comparative study.
M. Arvanitakis, B. Gulbis, J. Devière, M. Delhaye / ULB Erasme

10.15 T05 Patients suffering from chronic pancreatitis with an inflammatory mass in the pancreatic head benefit significantly from a Frey procedure at longterm follow-up.
F. Berrevoet, F. Goudsmedt, S. Laurent, X. Rogiers, R. Troisi, B. de Hemptinne / UZ Gent

10.30 T06 The interleukin-33 receptor ST2 down-regulates the severity of acute pancreatitis: a translational study in human and mice.
A. Lemmers, C. Moreno, M. Arvanitakis, R. Ouziel, D. Degré, E. Quertinmont, V. Vercruysse,
P. Demetter, O. Le Moine, A.N. Mckenzie, M. Delhaye, J. Devière, T. Gustot / ULB Erasme

10.45 T07 Genetic and phenotypic characterization of patients with chronic or recurrent “genetic” pancreatitis.

11.00 COFFEE BREAK

MODERATORS: P. PELKMANS, M. DELHAYE

11.30 T08 INVITED LECTURE: New advances in genetics and pancreatic diseases.
C. Cano / INSERM, Marseille, France.

12.00 T09 Diagnosis and histological confirmation of diffuse Merkel cell carcinoma relapse by endosonography.
P. Gast / ULg Sart Tilman

W. Van Steenbergen / KULeuven Gasthuisberg

12.30 T11 Incidental finding of a pancreatic cystic lesion with a very high CEA level in cyst fluid.
M. Delhaye, M. Arvanitakis, S. Debroux, P. Eisendrath, P. Demetter, C. Matos, J. Closset / ULB Erasme
**CHAIREDEN** : F. MANA, D. FRANCHIMONT

**14.00 I01** INVITED LECTURE: “New trends in epidemiology of paediatric IBD”.
G. Veereman / Queen Paola Children’s Hospital, Antwerp

**14.20 I02** Prioritisation of mucosal protease /protease inhibitor candidate genes in inflammatory bowel disease through a systematic review analysis approach.

**14.30 I03** Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis.

**14.40 I04** Seroreactivity to faecalibacterium prausnitzii and the presence of this microorganism in feces of Crohn’s disease patients and controls.
N. Vermeulen, M. Joossens, S. Vermeire, P. Rutgeerts, X. Bossuyt / KULeuven

**14.50 I05** INVITED LECTURE: “Role of regulatory T cells in IBD”.
A. Izcue / Oxford, U.K.

**15.20** COFFEE BREAK

**CHAIREDEN** : E. LOUIS, J.F. RAHIER

**15.40 I06** INVITED LECTURE: “New ECCO consensus on extra-intestinal manifestations of Crohn’s disease”.
M. De Vos / UZ Gent

**16.10 I07** Schistosoma mansoni proteins attenuate murine experimental colitis: determination of T cell cytokines to unravel immunological pathways.

**16.20 I08** Surgical closure of Crohn’s rectovaginal fistulas in the era of biological therapies.

**16.30 I09** Increased intestinal VEGF expression and mucosal vascularization in patients with spondylarthropathy.
P. Hindryckx, G. Serry, D. Laukens, H. Peeters, M. De Vos / UZ Gent

**16.40 I10** INVITED LECTURE: “New therapeutic strategies in IBD: blocking the traffic to the gut”.
S. Ghosh / London, U.K. and Calgary, Canada

**17.30** End of the Program
SESSION 1

- **MODERATOR:** A. BURETTE

14.00 H01  **INVITED LECTURE:** « H. pylori and obesity/bariatric surgery ».  
R. Ntouenda / ULB, Saint-Pierre, Brussels

14.20 H02  **INVITED LECTURE:** « Pathology of Helicobacter suis in rodent models ».  
B. Flahou / Faculty of Veterinary Medicine, UGent

M. Deyi / ULB, Brugmann

15.00-15.30  **COFFEE BREAK**

SESSION 2 : TREATMENT OF H. PYLORI

- **MODERATOR:** S. CADRANEL

15.30 H04  20 years survey of prevalence of H. pylori in patients with ulcer disease.  
A. Burette / Nouvelle Clinique de la Basilique, Brussels

15.50 H05  The resistance in Brussels, prospectively, and the Maastricht Guidelines.  
S. Vandebosch, V. Mattens, F. Mana / UZ Brussels

16.10 H06  The sequential therapy in children.  
P. Bontems, M. Scaillon, S. Cadranel / Queen Fabiola Children’s Hospital, Brussels

16.30  **End of the Program**
**MODERATORS:** E. MACKEN, D. URBAIN

14.00  **V01**  Usefulness of capsule and optical enteroscopy in IBD.
A. Van Gossum / ULB Erasme

14.25  **V02**  Endoscopic devices for the exploration of the small bowel.
T. Moreels / UZ Antwerp

15.10  **V03**  Selected clinical cases (Quiz).
D. De Looze / UZ Gent

15.30  **V04**  What is the adequate preparation for the examination of the small bowel by videocapsule?
I. Demedts / KUL Gasthuisberg

16.00  End of the program
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>D01</td>
<td><strong>Visceral fat and insulin resistance are independently correlated to</strong>&lt;br&gt;<strong>degree of liver steatosis and stage of fibrosis in a non-selective cohort of obese patients.</strong>&lt;br&gt;L. Van Gaal, P. Michielsen / UZ Antwerp</td>
<td>S. Francque, A. Verrijken, I. Mertens, G. Hubens, E. Van Marck, P. Pelckmans,</td>
<td></td>
</tr>
<tr>
<td>14.10</td>
<td>D02</td>
<td><strong>Accuracy of clinical scoring systems for fatty liver and advanced liver fibrosis in an unselected overweight and obese population.</strong>&lt;br&gt;A. Verrijken, S. Francque, I. Mertens, P. Michielsen, L. Van Gaal / UZ Antwerp</td>
<td>A. Verrijken, S. Francque, I. Mertens, P. Michielsen, L. Van Gaal / UZ Antwerp</td>
<td></td>
</tr>
<tr>
<td>14.20</td>
<td>D03</td>
<td><strong>Determination of severe fibrosis and cirrhosis in alcoholic patients by transient elastography: a prospective comparison with liver biopsy.</strong>&lt;br&gt;F. Janssens, N. De Suray, Y. Horsmans, H. Piessevaux, P. De Timary, P. Stärkel / UCL Saint-Luc</td>
<td>F. Janssens, N. De Suray, Y. Horsmans, H. Piessevaux, P. De Timary, P. Stärkel / UCL Saint-Luc</td>
<td></td>
</tr>
<tr>
<td>14.50</td>
<td>D06</td>
<td><strong>Impact of Genotype and Ethnicity on the prevalence of Metabolic Syndrome associated with Chronic Hepatitis C.</strong>&lt;br&gt;ULB Saint-Pierre</td>
<td>T. Sersté, M. Nkuize, M. Van Gossuin, M. Reynders, R. Scheen, J.P. Mulkay /</td>
<td>ULB Saint-Pierre</td>
</tr>
<tr>
<td>15.00</td>
<td>D07</td>
<td><strong>INVITED LECTURE: Marc Hautekeete lecture:</strong>&lt;br&gt;<strong>resistance to HBV-HCV antiviral treatment.</strong>&lt;br&gt;F. Zoulim / Lyon, France</td>
<td>F. Zoulim / Lyon, France</td>
<td></td>
</tr>
<tr>
<td>15.40</td>
<td></td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Authors and Affiliations</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>-------</td>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td>16.00 D08</td>
<td>16.00 D08</td>
<td><strong>The value of fibroscan in prediction of variceal bleeding risk.</strong>&lt;br&gt;I. Ratiu, D. Lazar, A. Goldis, M. Strain, A. Deleanu, R. Sirli, A. Tudora, I. Sporea&lt;br&gt;Timisoara, Romania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40 D12</td>
<td>16.40 D12</td>
<td><strong>Bevacizumab and 5-Fu+oxaliplatin or irinotecan as neoadjuvant therapy for patients with non resectable liver metastases.</strong>&lt;br&gt;B. Van Den Bossche, K. Boterbergh, S. Laurent, I. Dero, F. Berrevoet, M. Peeters, B. de Hemptinne, R. Troisi / UZ Gent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.50 D13</td>
<td>16.50 D13</td>
<td><strong>Surgical management and prognostic factors of hilar cholangiocarcinoma (klatskin tumor): experience with 68 patients at the Ghent university hospital.</strong>&lt;br&gt;R. Troisi (1), A. Sagnotta (2), S. Laurent (1), I. Dero (1), T. Bocchetti (2), B. de Hemptinne (1) / [1] UZ Gent [2] St Andrea Hospital, La Sapienza II University of Rome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00 D14</td>
<td>17.00 D14</td>
<td><strong>Tumor recurrence after hepatectomy for colorectal liver metastases: The need for new predictive factors?</strong>&lt;br&gt;V. Lucidi, A. Buggenhout, B. Nebbot, J.L. Van Laethem, V. Donckier / ULB Erasme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.10 D15</td>
<td>17.10 D15</td>
<td><strong>Endoscopic treatment of biliary colics and pancreatitis during pregnancy: a series of 18 patients.</strong>&lt;br&gt;W. Van Steenbergen / KULeuven</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.20 D16</td>
<td>17.20 D16</td>
<td><strong>CXCR4 expression predict early relapse after adjuvant radiochemotherapy in patients with resected pancreatic adenocarcinoma.</strong>&lt;br&gt;R. Marechal, P. Demeteter, A. Berton, I. Salmon, J.L. Van Laethem / ULB Erasme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td>17.30</td>
<td><strong>End of the program</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Thursday, 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning</td>
<td><strong>Basl</strong></td>
</tr>
<tr>
<td>Lunch</td>
<td><strong>OG - FWO</strong></td>
</tr>
<tr>
<td>13H15-14H00</td>
<td><strong>Satellite Symposium Bayer</strong></td>
</tr>
<tr>
<td>Afternoon</td>
<td><strong>Joint Meeting</strong></td>
</tr>
<tr>
<td>17H30-18H15</td>
<td><strong>Satellite Symposium Schering Plough</strong></td>
</tr>
<tr>
<td>18H15-19H00</td>
<td><strong>Satellite Symposium Merck</strong></td>
</tr>
</tbody>
</table>

**Exhibition Area**: Belle Epoque Room

### Friday, 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning</td>
<td><strong>Joint Meeting</strong></td>
</tr>
<tr>
<td>Lunch</td>
<td><strong>Pathology / Radiology / BGDO</strong></td>
</tr>
<tr>
<td>13H15-14H00</td>
<td><strong>Satellite Symposium Danone</strong></td>
</tr>
<tr>
<td>Afternoon</td>
<td><strong>Joint Meeting</strong></td>
</tr>
<tr>
<td>17H30-18H15</td>
<td><strong>Satellite Symposium Nycomed</strong></td>
</tr>
<tr>
<td>18H15-19H00</td>
<td><strong>Satellite Symposium Gilead</strong></td>
</tr>
</tbody>
</table>

**Exhibition Area**: Belle Epoque Room

### Saturday, 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning</td>
<td><strong>Symposium of the 6 Societies</strong></td>
</tr>
<tr>
<td>Lunch</td>
<td><strong>Exhibition Area</strong></td>
</tr>
<tr>
<td>Afternoon</td>
<td><strong>BSGIE Committee Meeting</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium of the 6 Societies</strong></td>
</tr>
<tr>
<td>TIFFANY</td>
<td>FLORENTINE</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------</td>
</tr>
<tr>
<td>BELGIAN PANCREATIC CLUB</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>HP RESEARCH GROUP</td>
<td>INTERNET CORNER</td>
</tr>
<tr>
<td></td>
<td>INTERNET CORNER</td>
</tr>
<tr>
<td></td>
<td>INTERNET CORNER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BPESGHAN</th>
<th>BGDO</th>
<th>NUTRITION GROUP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>INTERNET CORNER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA / CS SRBGE</td>
<td>INTERNET CORNER</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INTERNET CORNER</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| XXI• BELGIAN WEEK OF GASTROENTEROLOGY • ANTWERP, FEBRUARY 12-14 2009 | 27
**MODERATORS**: S. FRANQUE, E. LOUIS, M. HIELE

**08.30 D17** Predictive value of C-reactive protein level changes on the long term outcome of infliximab in Crohn’s disease.

**08.45 D18** Surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis from colorectal cancer: hope or hype?
W. Ceelen, Y. Van Nieuwenhove, D. Vande Putte, M. Peeters, P. Pattyn / UZ Gent

**09.00 D19** The potential role of hent1 as a predictive factor in advanced cholangiocarcinoma treated with gemcitabine: a retrospective analysis.

**09.15 D20** Impaired butyrate oxidation is closely linked to the sulphide detoxification capacity of the mucosa in ulcerative colitis.
V. De Preter, I. Arijs, E. Houben, S. Vermeire, P. Rutgeerts, K. Verbeke / KULeuven Gasthuisberg


**09.45 D22** Long-term survival in patients with non severe alcoholic hepatitis.
D. Degré, A. Lemmers, T. Gustot, R. Maréchal, S. Evrard, M. Adler, O. Le Moine, J. Devière, C. Moreno / ULB Erasme

**10.00 D23** Comparison between laparoscopic, transgastric and transcolonic peritoneal exploration and laparoscopic ultrasonography in pigs.

**10.15 D24** Conversion from calcineurin inhibitor therapy to everolimus in long-term liver transplant patients: results of a prospective, randomized, multicenter trial.

**10.30** COFFEE BREAK
**MODERATORS**: B. DE HEMPTINNE, H. PIESSEVAUX, H. LOUIS

**11.00 D25** Endoscopic EMR or ESD in long (L), extra-long (XL) and extra-extra-long (XXL) Barrett’s esophagus: do we really need surgery or ablation techniques?


**11.15 D26** Low molecular weight heparin inhibits tumor associated angiogenesis in vivo.

I. Debergh, N. Van Damme, P. Pattyn, M. Peeters, W. Ceelen / UZ Gent

**11.30 D27** Intestinal transplantation: an analysis of the international intestinal transplant registry.


**11.45 D28** Infliximab discontinuation in Crohn’s disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study.


**12.00 D29** Efficacy of pre-treatment biopsies in predicting final histopathology of endoscopically resected early malignancies in the upper gastrointestinal tract.

R. Bisschops, G. De Hertogh, J. Beck, P. Nafteux, K. Geboes, A. Lerut / KULeuven

**12.15 D30** Effects of delayed introduction of calcineurin inhibitor on GFR in liver transplant: 12 month data from a multi-centre randomised controlled study.


**12.30 D31** An early decision for ptfe-covered-transjugular intrahepatic portosystemic shunt improves survival in high risk cirrhotic patients admitted with an acute variceal bleeding: results from an international multi-center randomized controlled trial.


**12.45** News from the Gastroenterology Professional Union.

J.L. Coenegrachts, P. Van Hootegem, P. Deprez

**13.00** LUNCH
14.00 D32 Significant reduction of iron need in IBD patients after initiation of anti TNF treatment.
H. Pilate (1), G. Van Assche (2), S. Vermeire (2), G. Van Olmen (1), K. Katsanos (2),
__________
P. Rutgeerts (2), G. D’Haens (1) / [1] Imelda General Hospital, Bonheiden, [2] KULeuven

14.20 D33 Increasing incidence of clostridium difficile-associated diarrhea in inflammatory bowel disease.
P. Bossuyt, J. Verhaegen, G. Van Assche, P. Rutgeerts, S. Vermeire / KULeuven

14.30 D34 Psoriasis and eczema skin lesions associated with TNF-blockade therapy in IBD: natural history and clinical characteristics.
Y. Bouhnik (6), E. Delaporte (2), J.F. Colombel (2) / [1] UCL Mont Godinne, Belgium,
__________

14.40 D35 Long term outcome of palliative treatment with stent and/or chemotherapy for obstructing carcinoma of the colon.
C. Breynaert, J. Vandervoort, M. De Man, P. Van Der Spek, K. Hendrickx, J. Vanstiphout,
L. Duville, F. Sermon, L. Lepoutre / Onze-Lieve-Vrouw Ziekenhuis, Aalst

14.50 D36 Endoscopic submucosal dissection : preliminary results of an european center.
A. Badaoui (1), E. Bories (2), C. Pesenti (2), F. Caillol (2), G. Monges (2), J.R. Delpero (2),
M. Giovannini (2) / [1] UCL Mont-Godinne, Belgium, [2] Paoli-Calmettes Institute,
__________
Marseille, France

15.00 D37 One year weight loss in first 21 patients treated with new transoral gastric stapling system.
C. Moreno (1), G. Ojeda Valdes (2), L.F. Cuevas Herrera (2), J. Closet (1), A. Mehdi (1),
P. Eisendrath (1), S. Dugardeyn (1), M. Baréa (1), M. Zalcman (1), O. Le Moine (1),
__________
J. Devière (1) / [1] ULB Erasme, Brussels, [2] Hospital Regional 1st Octubre, Mexico City, Mexico

D38 Transoral gastroplasty (toga) for obesity results of second phase multi-center study.
C. Moreno (1), G. Ojeda Valdes (2), G. Costamagna (3), L.F. Cuevas Herrera (2),
J. Closet (1), A. Mehdi (1), P. Eisendrath (1), S. Dugardeyn (1), M. Baréa (1),
E. Coppens (1), O. Le Moine (1), J. Devière (1) / [1] ULB Erasme, Brussels,
__________
[2] Hospital Regional 1st Octubre, Mexico City, Mexico, [3] Catholic University, Roma, Italy

15.15 D39 Improving patient process and cycle time during colonoscopy with the lean & six sigma methodology.
E. Raymakers, H. Piessevaux, B. Debande, O. Dewit, K. Azzouzi, M.A. Denis,
D. Vandenbosch, I. Perez Y Mira, P. Deprez / UCL Saint-Luc

S. De Rouck, P. Hindryckx, M. De Vos, D. De Loose / UZ Gent

15.35 COFFEE BREAK
16.00 D41 Dumping syndrome following Nissen fundoplication in children.
B. De Muynck, T. Bosmans, I. Hoffman / KULeuven Gasthuisberg

16.10 D42 Efficacy and safety of 12-week treatment with prucalopride in patients with severe chronic constipation: combined results of 3 identical, double-blind, placebo-controlled trials.

16.20 D43 Accuracy of a simplified IBS self-report questionnaire compared to the Rome III criteria in distinguishing IBS from organic disease.

16.30 D44 Laryngeal neuropathy in patients with persisting globus sensation.

R. Bisschops, A. Lerut, I. Demedts, G. De Hertogh, P. Nafteux, K. Geboes, P. Rutgeerts / KULeuven

16.50 D46 Postoperative complications after transthoracic esophagectomy for Esophageal and Gastroesophageal junction (GEJ) cancer are negatively affecting onset of early recurrence.

17.00 D47 Complete pathological response after neoadjuvant chemoradiotherapy for stage II and III rectal adenocarcinoma predicts excellent long-term outcome.
A. Wolthuis, F. Penninckx, K. Haustermans, E. Van Cutsem, A. Dhoore / KULeuven

17.10 D48 Comparison of the colonic metabolite fingerprint in chronic kidney disease with healthy state.

17.20 End of the program
08.30  P01  Aggressive systemic mastocytosis : about a case of intestinal presentation.

08.40  P02  Evaluation of the use of intralesional cidofovir in the treatment of intra-anal condylomata acuminata with dysplasia.

08.50  P03  Comparative expression of glypican 3 on cofetal protein on human hepatocellular carcinoma cells and their tumours in nude mice.

09.00  P04  The angiostatic chemokine platelet factor-4 variant (PF-4VAR/CXCL4L1) is expressed in human gastrointestinal cancer.

09.10  P05  EMR for superficial esophageal neoplasms : a comparison of diagnosis on pre-EMR biopsies and EMR specimens.
J. Beck, K. Geboes, G. De Hertogh, P. Van Eyken, R. Bisschops / UZ Leuven

09.20  P06  MDM2 overexpression is associated with restricted pattern of P53 overexpression and inversely correlates with TP53 mutation in colorectal cancer.
C. Nyiraneza, C. Sempoux, P. Camby, A. Kartheuser, R. Detry, K. Dahan / UCL

9.30  P07  A carcinosarcoma of the rectum, an uncommon tumour, composed of two relatively rare neoplastic components.
M. Abdul-Hamid, R. Riedl, I. Van Den Bosch, F. Bakers, A. Oosterkamp, A. Driessen / University Hospital Maastricht, The Netherlands

9.40  P08  Usefulness of p53 and p504S (racemase) for the diagnosis of Barrett’s intraepithelial neoplasia.
K. Ho Minh Duc, C. Sempoux, H. Piessevaux, P. Deprez, A. Jouret-Mourin / UCL Saint-Luc

9.50  P09  Confocal laser endomicroscopy of colorectal neoplasia : a systematic analysis by the pathologist.
A.S. Van Rompuy, K. Geboes, G. De Hertogh, P. Rutgeerts, R. Bisschops / KULeuven

10.00  COFFEE BREAK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30</td>
<td>P10</td>
<td>INVITED LECTURE: Colorectal cancer, KiRAS and the pathologist.</td>
<td>J. Van Krieken / Nijmegen, The Netherlands</td>
</tr>
<tr>
<td>11.00</td>
<td>P11</td>
<td>Primary small-cell carcinoma of the pancreas: An analysis of 23 cases reported in the literature.</td>
<td>B. Vos, A. Awada, A. Hendlisz / Institut Bordet Brussels</td>
</tr>
<tr>
<td>11.10</td>
<td>P12</td>
<td>The ras inhibitor farnesylthiosalicylic acid inhibits the growth of hepatocarcinoma cell lines in vitro and in vivo.</td>
<td>N. Charette, V. Lannoy, C. De Saeger, I. Leclercq, Y. Horsmans, P. Stärkel / UCL Saint-Luc</td>
</tr>
<tr>
<td>11.20</td>
<td>P13</td>
<td>Diffuse peritoneal lymphomatosis in a patient with Crohn’s disease treated with immunosuppressive therapy.</td>
<td>E. Willems, G. De Hertogh, F. Claus, D. Vanbeekenvoort, K. Van Pelt / KULeuven</td>
</tr>
<tr>
<td>11.30</td>
<td>P14</td>
<td>Pet evaluation of anti-VEGF treatment in combination with chemotherapy in MCRC.</td>
<td>N. Van Damme, C. Van De Wiele, W. Ceelen, S. Laurent, I. Dero, K. Geboes, B. Lambert, P. Smeets, M. Peeters / UZ Gent</td>
</tr>
<tr>
<td>12.15</td>
<td></td>
<td>LUNCH</td>
<td></td>
</tr>
</tbody>
</table>
MODERATORS: N. NAGY, B. OP DE BEECK

13.30 P16  INVITED LECTURE: How close can be the radiologist with the pathologist for the local staging of colo-rectal cancer?
E. Danse et al. / UCL

14.00 P17  Unusual features in a liver biopsy leading to an unsuspected diagnosis.

14.10 P18  Iconography of liver lesions of patients with hereditary hemorrhagic telangiectasia.
X. Chapaux, R. Brenard / Hôpital St-Joseph, Gilly

14.20 P19  Double granular cell tumor of the distal oesophagus.
G. De Hertogh, J. Coolen, G. Vanneste, R. Vanslembrouck, D. Vanbekevoort / UZ Leuven

14.30 P20  About an uncommon cause of intestinal mechanical obstruction.
E. Danse, C. Sempoux, A. Jouret-Mourin, J. Donnez / UCL Saint-Luc

14.40 P21  Multifocal epithelioid angiosarcoma of the small bowel.
G. De Hertogh, R. De Wyngaert, R. Vanslembrouck, E. Wisanto, D. Vanbekevoort / UZ Leuven

14.50 P22  Combined hepatocellular and cholangiocellular carcinoma with radiological characteristics of focal nodular hyperplasia.

15.00 P23  NSAID-induced diaphragm disease of the right colon: report of a case and review of the literature.
E. Vanderlinden, A. Cheragwandi, F. Mana, F. Vandenbroucke, G. Delvaux, A. Hoorens / UZ Brussel

15.10 P24  Intraductal development of pancreatic neuroendocrine tumours.
A. Mathieu, M.A. Bali, N. Nagy, J. Closset, A. Negulescu, M. Delhaye, C. Matos, P. Demetter / ULB Erasme

15.20 P25  Unusual presentation of an insulinoma.
P. Meunier, J.F. Monville, I. Scagnol, E. Hamoir / University Hospital ULg

15.30  COFFEE BREAK
16.00 P26 **INVITED LECTURE:** Radiological-pathological correlations in the staging of chronic liver disease.

J. Cobbold / London, U.K.

16.30 P27 **Intraductal Papillary Mucinous Neoplasm of the Pancreas:**
Radiological-Pathological correlation.

16.40 P28 **A case of glucagonoma: correlation between clinical, radiological and histological findings.**
A. Van Landeghem / UZ Gent

16.50 P29 **Unusual presentation of liver adenoma: case report.**
P. Sierens / UZ Brussel

17.00 P30 **Groove’s pancreatitis and cystic dystrophy of the duodenal wall: rare cause of severe epigastric pain.**
A. Snoeckx, G. Van Den Eynden, B. Op De Beeck, T. Chapelle, I. Brosius, P. Parizel / UZ Antwerp

17.10 P31 **Diffusion magnetic resonance imaging as surrogate marker to anti-VEGF treatment response in mCRC?**
P. Smeets, N. Van Damme, W. Ceelen, C. Vande Walle, C. Van De Wiele, I. Dero, K. Geboes, S. Laurent, M. Peeters / UZ Gent

17.20 P32 **Comparison of two contrast agents for DCE-MRI evaluation of anti-VEGF treatment in combination with chemotherapy in mCRC.**
P. Smeets, N. Van Damme, W. Ceelen, C. Vande Walle, C. Van De Wiele, I. Dero, K. Geboes, S. Laurent, M. Peeters / UZ Gent

17.30 **End of the program**
**MODERATORS:** M. PEETERS, M. POLUS

**14.00 O01** INVITED LECTURE: Treatment of cancer of the oesophagus and GE junction: lessons of 2000 oesophagectomies.
---
T. Lerut / UZ Leuven

**14.30 O02** Small-cell carcinoma of the oesophagus: a multicentre, retrospective study of the Rare Cancer Network.
---

**14.40 O03** Phase II study of preoperative helical tomotherapy for rectal cancer.
---

**14.50 O04** Sigmoid colon cancer with metastasis: resection of the primary tumour followed by palliative chemotherapy versus palliative chemotherapy alone.
---

**15.00 O05** Major hepatectomies increases the risk of morbidity and mortality in simultaneous resection of synchronous liver metastases and colorectal cancer.
---
B. Van Den Bossche, K. Boterbergh, S. Laurent, I. Dero, F. Berrevoet, M. Peeters, B. de Hemptinne, R. Troisi / UZ Gent

**15.10 O06** Defining the optimal therapy sequence in synchronous resectable liver metastases from colorectal cancer: a decision analysis approach.
---
E. Van Dessel, K. Fieren, P. Pattyn, Y. Van Nieuwenhove, M. Peeters, N. Van Damme, F. Berrevoet, W. Ceelen / UZ Gent

**15.20** COFFEE BREAK

**MODERATORS:** E. VAN CUTSEM, I. BORBATH

**15.50** ASCO GI HIGHLIGHTS 2009:
- Upper GI tract cancers. M. De Man / OLV Aalst
- Hepato-biliary and pancreatic cancers. C. Verslype / KUL
- Colorectal cancers. M. Peeters / UZG
- Discussion and key points. E. Van Cutsem / KUL

**17.15** End of the program
### SESSION 1

**MODERATORS**: M. SCAILLON, M. HIELE

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td><strong>E01</strong> Challenges for transitional care: transfer or transition?</td>
<td>J. Van De Walle / UZ Gent</td>
</tr>
<tr>
<td>14.20</td>
<td><strong>E02</strong> Educational aspects to optimize transitional process.</td>
<td>I. Aujoulat / UCL Bruxelles</td>
</tr>
<tr>
<td>14.40</td>
<td><strong>E03</strong> Transition of IBD patients from paediatric to adult specialist. Important considerations and a proposal for transition chart.</td>
<td>G. Veereman-Wauters (1), H. Peeters (2) / [1] Queen Paola Children’s Hospital Antwerp, [2] UZ Gent</td>
</tr>
<tr>
<td>15.10</td>
<td><strong>E04</strong> Home Artificial Nutrition: from the baby to the adult.</td>
<td>P. Schlesser / CHC Clinique l’Espérance Liège</td>
</tr>
<tr>
<td>15.30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2

**MODERATORS**: M. VAN WINCKEL, R. FIASSE

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td><strong>E05</strong> New NASPGHAN-ESPGHAN GOR-guidelines.</td>
<td>Y. Vandenplas / UZ Brussel</td>
</tr>
<tr>
<td>16.15</td>
<td><strong>E06</strong> Approach of GOR in the adult.</td>
<td>H. Louis / ULB Erasme</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>E07</strong> Living with celiac disease: quality of life as assessed by parents and children/adolescents.</td>
<td>A. Vanoppen, B. Gers, P. Alliet / Virga Jesse Ziekenhuis Hasselt</td>
</tr>
<tr>
<td>16.45</td>
<td><strong>E08</strong> Adult patient experience with celiac disease since childhood.</td>
<td>S. Pierard / UCL, Société Belge de la Coeliaquie</td>
</tr>
<tr>
<td>17.00</td>
<td><strong>End of the Program</strong></td>
<td></td>
</tr>
</tbody>
</table>
**MODERATORS**: D. YSEBAERT, F. MOKADEM

**14.00 N01**  
**Nutrition Day in 2007 in Europe and Belgium.**  
J.C. Preiser / ULg

**14.15 N02**  
**Nutritional assessment of patients undergoing elective colorectal resection for cancer.**  
L. Moerman, E. De Waele, S. Mattens, B. De Waele, G. Delvaux / UZ Brussels

**14.30 N03**  
**Weight loss as the most powerful predictor of postoperative mortality and morbidity after surgery for head and neck cancer.**  
L. Pire, P. Demez, P. Moreau, P.P. lefebvre, J.C. Preiser / ULg

**14.45 N04**  
**Home care and Care Homes: strategy for implementing adequate nutrition. Report of the Council of Europe (4 Dec 2008).**  

**15.00 N05**  
**Preliminary Results of Nutriaction.**  

**15.15**  
**Discussion**

**15.30**  
**COFFEE BREAK**

**16.00 N06**  
**Is transient elastography (Fibroscan®) valuable for assessing liver fibrosis in patients with long-term Home Parenteral nutrition (HPN)? Preliminary results.**  

**16.15 N07**  
**The role of the nutrition nurse in the teaching and follow-up of patients on long-term home parenteral nutrition.**  
A. Ballarin and Nutrition Team / ULB Erasme

**16.30 N08**  
**The supplementation of 10g/day arabinoxylo-oligosaccharides, a newly proposed prebiotic, to the diet of healthy subjects is well tolerated.**  
L. Cloetens, W. Broekaeart, C. Courtin, J. Delcour, P. Rutgeerts, K. Verbeke / LFoRCe

**16.45 N09**  
**The increased level of bifidobacteria and a beneficially modulated colonic metabolic activity suggest the prebiotic potential of arabinoxylo-oligosaccharides in healthy subjects.**  

**17.00**  
**End of the Program**
A18  Confirmation of candidate serum markers of hepatitis C-related fibrosis following serum proteomics.
    K.J. Cheung, K. Tilleman, D. Deforce, I. Colle, H. Van Vlierberghe / UZ Gent

A19  Liver transplantation for subacute hepatocellular failure after scopinaro (Biliopancreatic diversion).
    S. Rogge, H. Van Vlierberghe, A. Geerts, R. Troisi, F. Berrevoet, X. Rogiers, B. de Hemptinne, I. Colle / UZ Gent

A20  Mycophenolate mofetil monotherapy in stable liver transplant patients with calcineurin inhibitor related toxicity.

A21  Influence of adipocytokines on sinusoidal liver cells.
    B. Schroyen, S. Knops, C. Empsen, L. Van Grunsven, A. Geerts / VUB

A22  Evaluation of the JAK2 V617F mutation in a series of patients with idiopathic splanchic vein thrombosis.
    V. Michels, O. Plomteux, B. Bastens, H. Charlier, D. Brisbois, F. Fontaine / CHC Liège

A23  Isolation and facs-based purification of liver sinusoidal cells.
    C. Empsen, E.L. Guimaraes, B. Schroyen, S. Knops, L. Van Grunsven, A. Geerts / VUB

A24  Upper gastrointestinal bleeding in cirrhosis: what has changed during the last 20 years?
    J. Henrion, P. Deltenre, S. De Maeght, J.M. Ghilain, J.M. Maisin, M. Moulart, T. Delaunoit, D. Verset,
    C.P. Yeung, M. Schapira / Hôpital Jolimont

A25  Results of liver transplantation from controlled donation after cardiac death (DCD) donors: a single centre experience.

A26  Role of the cirrhosis risk score for the prediction of fibrosis progression in hepatitis C patients with minimal liver disease.

A27  Different N-Glycosylation patterns in mice models of portal hypertension and cirrhosis.

A28  Serum proteomics in fibrotic Hepatitis C patients.

A29  Insulin induces oxidative stress, but no metabolic effects on mouse hepatic stellate Cells.
    S. Knops, B. Schroyen, L. Van Grunsven, E.M. Guimaraes, H. Reynaert, A. Geerts / VUB
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. Additional information is available on the Internet at www.roche.be.
Satellite symposium
Schering-Plough
«Landmark data in IBD patients»

Tuesday February 12
at 17:30
Teun - 3rd floor
E09  Ten years outcome analysis of isolated and combined liver transplantation in children listed for elective and high urgent transplantation: single institutional experience.

E10  Double-balloon enteroscopy in pediatric patients: experience of two university hospital endoscopy units.

E11  Pediatric Intervention Study With A Probiotic Mixture (Bacilac Forte) In Acute Gastroenteritis.

E12  Profile of Belgian pediatric Crohn’s disease subjects (2): snap shot at diagnosis.

E13  Oesophageal eosinophilic infiltration: meaning and evolution in paediatrics.
L. Muysront, P. Bontems, A. Salame, C. Deprez, S. Cadranel, M. Scaillon / ULB Reine Fabiola

E14  Pediatric intestinal transplantation.

E15  The additional value of multichannel intraluminal impedance in the detection of gastroesophageal reflux in children with pulmonary symptoms.
K. Cosyns, J. Tack, I. Hoffman / KULeuven Gasthuisberg

E16  Profile of belgian pediatric Crohn’s disease subjects (1): demography and background of the first 100 patients.
**D48**  Biliary complications in living donor liver transplantation: an invariable and significant morbidity irrespective of the operative approach. Comparison between two different institutional experiences.

**D49**  Marginal ulcers after laparoscopic gastric bypass: a retrospective study of 348 patients.
L. Kohnen, P. Tromme, P. Honoré, J. De Flines, J. Belaïche, M. Meurisse, A. De Roover / ULg Sart-Tilman

**D50**  The role of body mass index and waist circumference in determining reflux pattern and proximal extent of reflux events.
E. Scarpellini, K. Blondeau, R. Vos, J. Tack / KU Leuven

**D51**  Tolerance of selective and conventional chemoembolization for hepatocellular carcinoma.

**D52**  Liver transplantation outcome and MELD allocation system.
M. Sainz-Barriga (1), E.L. Decoster (1), F. Goudsmedt (1), K. Boterbergh (1), B. Van Den Bossche (1),
F. Berrevoet (1), A. Geerts (1), I. Colle (1), H. Van Vlierberghe (1), X. Rogiers (1), B. de Hemptinne (1),
R. Troisi (1) / [1] UZ Gent

**D53**  Endoluminal fundoplication (esophyx®) in GERD patients refractory to PPI therapy effect on symptoms, PPI use and distensibility.
J. Arts, L. Holvoet, R. Bisschops, P. Caenepeel, D. Dewulf, R. Vos, T. Degroof, D. Sifrim, T. Lerut, P. Rutgeerts,
J. Tack / KU Leuven

**D54**  Completion rate of conventional colonoscopy: reasons for failure and alternatives after unsuccessful intubation of the cecum.
N. Messaoudi, T. Moreels, P. Pelckmans / UZ Antwerp

**D55**  The first prospective endoscopic experience with the EPTFE-covered viabili stent in patients with a distal malignant biliary stenosis.
W. Van Steenbergen / KU Leuven Gasthuisberg

**D56**  Differential gene expression profile of the liver in a 24-hour porcine model of fluid-resuscitated fecal peritonitis.
H. Van Malenstein, J. Wauters, P. Van Hummelen, H. Cauwenberghs, K. Reynders, M. Van Wambeke,
L. Langouche, A. Wilmer, J. Van Pelt / KU Leuven Gasthuisberg

**D57**  Cigarette smoke induces apoptosis in the follicle-associated epithelium of murine peyer's patches.
S. Verschuere (1), P. Vlumens (1), P. Verbrugghe (2), K. Bracke (3), I. Rottiers (1), G. Brusselle (3),
**POSTER SESSION**

**JOINT MEETING**

**D58** Pooled pac-sym and pac-qol results from 3 identical, randomized, double-blind, placebo-controlled phase III trials with prucalopride in patients with severe chronic constipation.


**D59** Long-term outcome of transcatheter embolotheraphy for acute lower gastrointestinal hemorrhage.

G. Maleux, F. Roelraes, S. Heye, J. Vandersmissen, A.S. Vliegen, I. Demeur, A. Wilmer / KULeuven

**D60** Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia. The BASL registry based on 28 patients.


**D61** Comparison of epinephrine injection alone and epinephrine associated with bipolar coagulation in hemorrhagic gastro-duodenal ulcer.

A. Frère, R. Delrez, M. Lebas, B. Delhougne, M. Dartevelle, C. Gillard, F. Croës, D. Dresse, A. Denoël, C. Brixko, J. Deflandre / ULg

**D62** Colonoscopy in daily practice: a quality assessment study.

E. Vanderstraeten, P. Burvenich, K. Rasquin, E. Monsaert / Maria Middelares Ziekenhuis, Gent

**D63** Fecal transplantation for recurrent clostridium difficile colitis, an underused treatment modality.

S. Naegels, I. Ruytjens, L. Terriere, G. Blinder, J. Holvoet, R. Hellemans / Middelheim Hospital ZNA Antwerp

**D64** Endoscopic removal of dysfunctional rings or bands after vertical banded gastroplasty.

D. Blero, P. Eisendrath, A. Vandermeeren, O. Le Moine, J. Devière / ULB Erasme
PREMALIGNANT LESIONS IN
THE LIVER, PANCREAS AND
GASTROINTESTINAL TRACT

ORGANIZED BY THE BSGIE
BELGIAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY

08.15 Welcome
08.50 Introduction:
D. Urbain, P. Deprez

● MODERATORS: T. MOREELS, E. LOUIS

09.00 S01 Colorectal cancer precursors and non polypoid neoplastic lesions.
R. Lambert / Lyon, France

09.30 S02 The limits of polypectomy.
H. Piessevaux / UCL, Brussels, Belgium

09.50 S03 Risks of degenerescence in IBD.
G. Van Assche / KULeuven Gasthuisberg, Belgium

10.10 S04 Preneoplastic anorectal lesions.
D. De Looze / UZ Gent, Belgium

10.30 S05 Appropriateness of colonoscopy in Europe.
J.P. Vader / Lausanne, Switzerland

11.00 COFFEE BREAK

● MODERATORS: F. MANA, M. HIELE

11.30 S06 Premalignant lesions of the stomach.
A. de Vries / Rotterdam, The Netherlands

12.00 S07 Familial adenomatous polyposis: phenotype and genotype.
A. Munck / Paris, France

12.30 Awards of the Belgian Week of Gastroenterology
Best Clinical Joint Meeting Communication
Best Basic Science Joint Meeting Communication
(I. Colle, Scientific Coordinator of the Belgian Week of Gastroenterology)

BGDO Award (J.L. Van Laethem)
IBD Prize (R. Fiasse)

BSGIE Grant for clinical research (5000 €) (D. Urbain)

12.45 BSGIE General Assembly (P. van der Spek, secretary. New Board election)
13.00 LUNCH

14.00 S08 Brohée Prize Award & Lecture: (R. Fiasse)
«Role of vasoactive substances and cellular effectors in the pathophysiology of portal hypertension: a study on the cellular, organ, experimental animal and human level».
W. Laleman / KULeuven Gasthuisberg

14.15 BSGIE Grant 2007 winner
Endoluminal fundoplication (Esophyx®) in GERD patients refractory to PPI therapy: effects on symptoms, PPI dose and distensibility.
J. Arts / AZ St-Lucas Brugge

PREMALIGNANT LESIONS IN THE LIVER, PANCREAS AND GASTROINTESTINAL TRACT

MODERATORS: M. DE VOS, C. BERTRAND

14.30 S09 New evolutions in liver adenoma.
P. Bioulac-Sage / Bordeaux, France

15.00 S10 IPMT: The point of view of the surgeon.
J. Closset, V. Demoor / ULB Erasme, Brussels, Belgium

15.25 S11 Cystic pancreatic lesions: radiological approach and management.
B. Op de Beeck / UZ Antwerpen, UZ Brussels, Belgium

15.50 S12 Early detection of dysplasia and cancer in Barrett’s esophagus.
R. Bisschops / KULeuven Gasthuisberg, Belgium

P. Eisendrath / ULB Erasme, Brussels, Belgium

16.30 End of the Symposium.
ACCESS TO THE CONGRESS VENUE

Address:
Hilton Antwerp Hotel
Groenplaats – 2000 Antwerp
Tel: +32 3 204 12 12
Fax: +32 3 204 86 88.

Itinerary

Gent / Ghent (E17)
1. Immediately after the Kennedytunnel take exit n° 5A direction Antwerpen Centrum/ Zuid.
2. Keep left and drive through the Bolivartunnel.
3. Stay left and turn left at the first traffic lights
4. Follow Graaf Van Hoornestraat until the end follow right. Pass the Museum of fine arts on your right. Continue into the Volkstraat.
5. Follow the tram rails into the Nationalestraat.
6. At the end of the street, at the traffic lights you are facing the Groenplaats as well as the entrance of Parking Groenplaats.
7. The car park offers direct access to the hotel lobby.

Eindhoven / Hasselt (E34/E313)
1. At the end of the E34/E313 take the Ring direction Gent.
2. On the Ring take exit n° 5a direction Antwerpen Centrum/Zuid.
3. Stay left and turn left at the first traffic lights.
4. Follow the road for about 1 km until you arrive at the “Kaaien”. Turn right onto the “Kaaien”(alongside the Schelde).
5. At the fourth traffic lights turn right on the Suikerrui.
6. Follow the street until the first traffic lights and make a U-turn to the left.
7. Follow the tram rails to the traffic lights.
8. At the end of the street, at the traffic lights you are facing the Groenplaats as well as the entrance of Parking Groenplaats.
9. The car park offers direct access to the hotel lobby.

Brussel / Brussels (E19)
1. Just before the Craeybeckxtunnel take the second lane from the left direction Gent.
2. On the Ring stay right and take the first exit n° 5A direction Antwerpen Centrum/Zuid.
3. Turn left at the first traffic lights.
4. Follow the road straight ahead for about 1 km until you arrive at the “Kaaien”. Turn right onto the “Kaaien” (alongside the Schelde).
5. At the fourth traffic lights turn right again onto the Suikerrui.
6. Follow the street until the first traffic lights and make a U-turn to the left.
7. Follow the tram rails to the traffic lights.
8. At the end of the street, at the traffic lights you are facing the Groenplaats as well as the entrance of Parking Groenplaats.
9. The car park offers direct access to the hotel lobby.

Brussel / Brussels via Boom (A12)

1. Follow the A12 direction Antwerpen.
2. Just before the Jan Devostunnel stay left and follow direction Antwerpen Centrum/Zuid.
3. From here please see point 1 coming from Gent.

Zelzate / Leftbank (N49/E34)

1. Follow direction Antwerpen.
2. Drive through the Waaslandtunnel and immediately at the exit of the tunnel make a right turn of 45°.
3. Straight ahead onto the “Kaaien”. Onto the “Kaaien” (alongside the Schelde) turn left.
4. At the second traffic lights turn left onto the Suikerrui.
5. Follow the street until the first traffic lights and make a U-turn to the left.
6. Follow the tram rails to the traffic lights.
7. At the end of the street, at the traffic lights you are facing the Groenplaats as well as the entrance of Parking Groenplaats.
8. The car park offers direct access to the hotel lobby.

Breda (E19)

1. Follow E19/A1 direction Antwerpen.
2. On the Ring follow direction Antwerpen/ Gent/ Brussel
3. Take exit n°1 Antwerpen Noord/ Merksem and at the end of the exit turn right (Groenendaellaan)
4. At the third traffic lights turn left onto the Noorderlaan.
5. At the end of the Noorderlaan make a turn of 45° on a bridge. Keep right at the next traffic lights.
6. You arrive at the Londonstraat, straight ahead until you arrive at the “Kaaien”. Turn left onto the “Kaaien” (alongside the Schelde).
7. At the third traffic lights turn left onto the Suikerrui.
8. Follow the street to the first traffic lights and make a U-turn to the left.
9. Follow the tram rails to the traffic lights.
10. At the end of the street, at the traffic lights you are facing the Groenplaats as well as the entrance of Parking Groenplaats.
11. The car park offers direct access to the hotel lobby.

Parking :

Here are the closest parkings to the Hilton Antwerp :

- Groenplaats Parking: The Hilton Antwerp has reserved 200 places for our congress.
  Price per day: 13,5 €
- Meir Parking: Price per day: 13,5 €
- Brabo Parking: Price per day: 15 €
- Lombardia Parking: Thursday & Friday the price per day: 13,5 €
  Saturday the price per day: 15 €
FRIDAY NIGHT PARTY

at the Antwerp Zoo
in the exclusive « Marmeren Zaal »
on Friday February 13 at 8.00pm

The Belgian Week Steering Committee is looking forward to welcome all the registered participants and partners to the Friday Night Party!

The aperitif in the Winter Garden, dinner in the « Marmeren Zaal » with delicious food and nice music to follow…everything is there for an enchanting evening!

Make sure to join us and register on the websites:
www.belgianweek.be or www.bwge.be

Busses will leave from the Hilton Antwerp Hotel at 7.45pm. To come back: busses will leave the Zoo at 11.30pm and every 30 min, last bus at 1.30am.
PARTNERS 2009

PREMIUM PARTNERS

Abbott
AstraZeneca
Gilead

NYCOMED
Schering-Plough

MAJOR PARTNER

Bayer HealthCare
Bayer Schering Pharma
Roche

REGULAR PARTNERS

ACERTYS
ACTIAL FARMACEUTICA LDA
BENETEC
BIODIPHAR
BOSTON SCIENTIFIC BENELUX
BOUCCART MEDICAL
BRISTOL MYERS SQUIBB
COBRA MEDICAL
CODALI
COOK MEDICAL
DANONE
DUO-MED
DE BEUKELAER MEDICAL – PENTAX
ECCE DUTOIT
ECCO
ECHOSENS
ERBE BENELUX
EUMEDICA
FERRING
HITACHI MEDICAL SYSTEMS
IPSEN

MENARINI
MERCK
MOVETIS
NORGINE BELGIUM
NOVARTIS PHARMA
OLYMPUS BELGIUM
ONIS - FUJINON
ORPHAN EUROPE
OTSUKA PHARMACEUTICALS
RMS ENDOSCOPY
SOLVAY PHARMA
STICHTING VREEMDE
KRONKELS
STÖPLER BELGIUM
TBS - TELEMATIC & BIOMEDICAL SERVICES
TRAMEDICO
UCB PHARMA
UPTODATE
UEGW 2009 LONDON
VAN LOENEN INSTRUMENTS